List of high-quality authors
East Lake High-tech: It is planned to participate in the establishment of cutting-edge science and technology
East Lake High-tech announced that the company, the company's wholly-owned subsidiaries East Lake Investment, and Hubei Xia Chuang Xingyuan Industrial Investment Partnership (Limited Partnership) (hereinafter referred to as "Xia Chuang Xingyuan") plan to jointly initiate the establishment of cutting-edge science and technology. The scale of cutting-edge science and technology is 1200 million yuan, the company subscribed 58.8 million yuan, accounting for 49% of the largest scale; East Lake Investment subscribed and contributed 1.2 million yuan, accounting for 1% of the largest scale; Xia Chuangxingyuan subscribed and contributed 60 million yuan, accounting for 50% of the largest scale. Frontier Technology** will focus on investing in high-quality enterprises in the fields of intelligent manufacturing, integrated circuits, optoelectronic information, digital, new energy and new materials, health and other cutting-edge science and technology.
Guobang Pharmaceutical: Wholly-owned subsidiary passed GMP compliance inspection].
Guobang Pharmaceutical announced that the 308 workshop and apixaban production line of Zhejiang Guobang Pharmaceutical, a wholly-owned subsidiary, passed the GMP compliance inspection, indicating that the company's apixaban API product production quality management meets GMP requirements.
Aoyang Health: It is planned to acquire 51% of the shares of Anhui Daling for 20.4 million yuan
Aoyang Health announced that the company signed an equity purchase agreement with Wang Chaoqin to acquire 51% of the equity of Anhui Daling held by Wang Chaoqin for RMB 20.4 million.
East Asia Pharmaceutical: Plans to cooperate in the establishment of pharmaceutical investment** and jointly establish a pharmaceutical development company].
East Asia Pharmaceutical announced that it intends to jointly invest in the establishment of Taizhou Jiafu Zeli Equity Investment Partnership (Limited Partnership) with Jiafu Tiancheng, Taizhou Haisheng, Linhai Industrial Investment and Taizhou Kaitou, and subsequently jointly invest in the establishment of a pharmaceutical company specializing in the development of preparations, which will be independently developed by the pharmaceutical company or entrusted by CRO institutions to develop preparation products and apply for the drug registration certificate. The total subscribed capital contribution of the partnership is 1500 million yuan, of which Dongya Pharmaceutical subscribed and contributed 39 million yuan, holding 26% of the equity of the partnership.
Tonghua Dongbao: Phase clinical trial of gout dual-target inhibitor reached the primary endpoint target].
Tonghua Dongbao announced that its wholly-owned subsidiary, Dongbao Zixing (Hangzhou) Biopharmaceutical***, has completed a pivotal phase I clinical trial and obtained a clinical trial summary report after receiving the clinical trial approval notice issued by the National Medical Products Administration for gout dual-target XO Urat1 inhibitor (THDBH151 tablets).